data not shown for vehicle). In the EGSS score=4 subgroup, the difference between tazarotene 0.045% lotion and vehicle lotion was not statistically significant for the acne symptoms domain; however, significance was found in 2 acne symptom items (scabbing from acne and oily skin; P<0.05). Statistical significance in the EGSS score=4 subgroup was also found in 3 role-social items (meeting new people, going out in public, and interacting with the opposite sex or same sex if applicable; P<0.05).
Mean Acne-QoL improvements from baseline to week 12 were markedly greater in participants who self-reported worse quality of life at baseline (total score <60) than in participants with better quality of life (total score ≥60; Figure 3). In the Acne- QoL score ≥60 subgroup, statistical significance for tazarotene 0.045% lotion was found in the acne symptoms domain and in 2 acne symptoms items (bumps on face, bumps full of pus; P<0.05 vs vehicle lotion; data not shown for vehicle). In the Acne-QoL score <60 subgroup, statistical significance was also found in the acne symptoms domain, along with 3 acne symptom items (bumps on face, bumps full of pus, concerned with scarring; P<0.05). This subgroup with worse quality of life at baseline also had significantly greater mean improvements with tazarotene 0.045% lotion versus vehicle lotion in 1 role-emotional item (not looking my best) and 2 role-social items (meeting new people and interacting with the opposite sex or same sex if applicable; P<0.05).
Exploratory analyses indicated that mean Acne-QoL domain scores at baseline were lower (worse) in female versus male participants, as well as in Black versus White participants (Table 2). However, mean improvements in female and Black participants were relatively greater than those in male and White participants, resulting in comparable Acne-QoL scores at week 12.
